Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8+ T cells
{{output}}
Objectives: Bispecific antibodies targeting CD47 and PD-L1 (CD47 × PD-L1 BisAb) demonstrate efficacy against a range of solid cancers. While dual blockade negates anti-CD47-mediated toxicity, the effect of combined innate and ad... ...
